We see ALNA stock trading at $0.075 intraday on NASDAQ after a +3.16% move and 252,311,606 shares changing hands so far. The spike comes during a high-volume session with a day low of $0.06 and a day high of $0.1459. We track this most-active move in the biotech group and connect the intraday flow to company fundamentals, cash metrics, and short-term technical levels to help traders and investors make sense of the action.

Market snapshot for ALNA stock

ALNA stock is trading on the NASDAQ in the United States at $0.075 with a +3.16% intraday change. Volume is elevated at 252,311,606 shares versus no reported average volume. Intraday range is $0.06–$0.1459, open $0.0641, previous close $0.0727. The company sits in the Healthcare sector and Biotechnology industry and remains a thin-cap, high-volatility ticker for traders.

Why ALNA stock moved today

There is no fresh corporate press release driving today’s move. The price action looks driven by heavy intraday trading and speculative flows in penny biotech names. The large 252,311,606 share print suggests momentum traders and retail activity pushed the stock from the open $0.0641 toward the session high $0.1459 before a pullback toward the current $0.075 level.

Financials and valuation for Allena Pharmaceuticals (ALNA)

Allena Pharmaceuticals shows negative profitability with TTM EPS -0.64 and a reported PE ratio of -0.12. Key balance metrics include cash per share $0.92 and current ratio 2.11, which point to short-term liquidity. Price-to-book stands near 0.13, reflecting market pricing well below book value per share. Revenue per share is $0.00, and operating cash flow per share is -1.41, underscoring typical development-stage biotech burn.

Technical levels and intraday trading cues for ALNA stock

On the intraday chart, near-term support formed around the day low $0.06 and resistance clustered near the session high $0.1459. Traders should treat $0.06 as stop-conservative support and $0.12–$0.15 as a supply zone on strength. Lack of 50-day and 200-day averages limits trend context, so momentum and volume are primary short-term guides.

Meyka AI grade and what it means for ALNA stock

Meyka AI rates ALNA with a score out of 100: Score 62.62 | Grade B | Suggestion: HOLD. This grade factors S&P 500 benchmark comparison, sector and industry comparison, financial growth, key metrics, forecasts, analyst consensus and fundamental growth. The grade indicates mixed signals: decent liquidity ratios but persistent negative earnings and high volatility. These grades are informational only and not investment advice.

Risks and opportunities for Allena Pharmaceuticals (ALNA)

Opportunities include progress on ALLN-346 development and any regulatory updates that could re-rate the stock. Risks include ongoing R&D burn, no recent revenue, thin public float behavior, and clinical or regulatory setbacks common in Biotechnology. Given current metrics, ALNA stock remains speculative and more suited to traders who accept high downside risk.

Final Thoughts

Key takeaways: ALNA stock is a highly volatile NASDAQ-listed biotechnology name trading at $0.075 intraday with +3.16% movement and heavy volume 252,311,606 shares. Fundamentals show negative EPS -0.64, modest cash per share $0.92, and a price-to-book near 0.13. Meyka AI’s forecast model projects a 12-month reference target of $0.12, implying an upside of 60.00% versus the current $0.075 price. Forecasts are model-based projections and not guarantees. Traders should weigh the potential reward against high volatility, thin liquidity, and binary clinical risks typical for development-stage biotech. We will watch volume and any regulatory news as primary short-term triggers for further moves. For context on market-wide flows in equities and commentary, see Reuters and The Wall Street Journal source source. Meyka AI is our AI-powered market analysis platform and this note is data-driven market analysis, not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.